Foghorn Therapeutics entered the second half of 2026 as a different company than the one that closed out 2025, and the second-quarter print made the transition legible. The collaboration with Eli Lilly that funded much of its discovery engine is winding toward the December 2026 research-term expiration, and the accounting echo of that wind-down arrived in the form of a $14.2 million cumulative catch-up adjustment that lifted collaboration revenue to $16.1 million for the quarter. Net loss narrowed to $7.2 million from $17.9 million a year earlier, operating expenses fell across both research and general lines, and the balance sheet finished the period with $167.6 million in cash, cash equivalents and marketable securities. None of those numbers changes the fundamental bet, which is that FHD-909, the first-in-class SMARCA2 selective inhibitor co-developed with Lilly, validates its synthetic lethal mechanism in a Phase 1 dose escalation study now enrolling patients with SMARCA4-mutant non-small cell lung cancer. What the quarter does is sharpen the timeline: the wholly-owned EP300, CBP and ARID1B degrader programs, plus a novel oral molecule in immunology and inflammation, all target investigational new drug filings in 2027. The company is effectively trading the fading research-phase economics of the Lilly deal for the option value of a broad, partner-free clinical pipeline.
The investment case rests on three variables that the market can track quarter to quarter. The first is the pace of the FHD-909 Phase 1 program, where enrollment in the dose escalation study determines when the company can begin combination testing with pembrolizumab in non-small cell lung cancer. Management has tied that event to successful dose escalation. The second is the delivery of the wholly-owned IND pipeline in 2027, starting with the selective EP300 degrader aimed at multiple myeloma and diffuse large B-cell lymphoma and the undisclosed immunology and inflammation molecule. Each filing converts platform claims into clinical assets with discrete value. The third is cash runway, where $167.6 million against an annualized operating burn near $86 million supports operations into the first half of 2028 and gives management room to reach those filings without an immediate financing. Each variable carries a visible data signal: enrollment and dose escalation updates for FHD-909, IND announcements for the degraders, and the quarterly cash position against the trailing burn rate.
What confirms the thesis is a sequence of specific events rather than a single print. Completion of FHD-909 dose escalation without dose-limiting toxicity flags, followed by the initiation of pembrolizumab combination cohorts, would validate the mechanism in the clinic and pull forward the Lilly-linked economics. An IND filing for the EP300 degrader and the immunology molecule in 2027 would demonstrate that the platform produces clinical candidates on schedule. Updated guidance on the delayed CBP degrader program would clear the one visible execution blemish. What breaks the thesis is equally concrete: a safety or efficacy failure in the FHD-909 study, an extension of the CBP degrader delay into 2027, or a capital raise before the pipeline reaches its inflection. The stock near $6.00 with a market capitalization around $356 million and an enterprise value near $232 million leaves little room for another year of timeline slippage without a repricing toward cash.